Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 277,483
  • Shares Outstanding, K 149,991
  • Annual Sales, $ 3,520 K
  • Annual Income, $ -11,710 K
  • 60-Month Beta 1.93
  • Price/Sales 102.23
  • Price/Cash Flow 12.15
  • Price/Book 3.09
Trade LCTX with:

Options Overview

Details
  • Implied Volatility 244.71%
  • Historical Volatility 99.60%
  • IV Percentile 38%
  • IV Rank 14.46%
  • IV High 1,027.17% on 07/02/20
  • IV Low 112.45% on 01/11/21
  • Put/Call Vol Ratio 0.05
  • Today's Volume 662
  • Volume Avg (30-Day) 1,237
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 29,206
  • Open Int (30-Day) 28,014

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +19.35%
on 03/05/21
3.1316 -40.92%
on 02/17/21
-0.6900 (-27.17%)
since 02/05/21
3-Month
1.5400 +20.13%
on 12/07/20
3.1316 -40.92%
on 02/17/21
+0.2400 (+14.91%)
since 12/04/20
52-Week
0.5801 +218.91%
on 03/18/20
3.1316 -40.92%
on 02/17/21
+0.9001 (+94.76%)
since 03/05/20

Most Recent Stories

More News
Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LCTX : 1.8500 (-0.54%)
Thinking about buying stock in Dare Bioscience, Endra Life Sciences, Lineage Cell Therapeutics, Inuvo Inc, or eMagin Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NDRA, LCTX, INUV, and EMAN.

EMAN : 4.18 (-3.91%)
INUV : 1.1000 (-4.35%)
LCTX : 1.8500 (-0.54%)
DARE : 1.9400 (+2.65%)
NDRA : 2.22 (+4.23%)
Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock?

Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.

LCTX : 1.8500 (-0.54%)
Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.8500 (-0.54%)
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

PCRX : 69.20 (+2.95%)
ABEO : 2.01 (-3.37%)
MNLO : 1.3500 (-2.17%)
LCTX : 1.8500 (-0.54%)
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.

AGN : 193.02 (+0.02%)
EDIT : 41.63 (+3.15%)
MNLO : 1.3500 (-2.17%)
LCTX : 1.8500 (-0.54%)
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.

ACAD : 48.98 (+6.90%)
ABEO : 2.01 (-3.37%)
MNLO : 1.3500 (-2.17%)
LCTX : 1.8500 (-0.54%)
Is Lineage Cell Therapeutics (LCTX) Outperforming Other Medical Stocks This Year?

Is (LCTX) Outperforming Other Medical Stocks This Year?

LCTX : 1.8500 (-0.54%)
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates....

ACAD : 48.98 (+6.90%)
NBRV : 1.7900 (+2.29%)
KALA : 7.12 (+0.42%)
LCTX : 1.8500 (-0.54%)
Will Lineage Cell Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics

LCTX : 1.8500 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 2.3937
2nd Resistance Point 2.1649
1st Resistance Point 2.0075
Last Price 1.8500
1st Support Level 1.6213
2nd Support Level 1.3925
3rd Support Level 1.2351

See More

52-Week High 3.1316
Fibonacci 61.8% 2.1569
Fibonacci 50% 1.8558
Last Price 1.8500
Fibonacci 38.2% 1.5548
52-Week Low 0.5801

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar